Ocular immunology and inflammation
-
Ocul. Immunol. Inflamm. · Jul 2020
Detection of SARS-CoV-2 in Human Retinal Biopsies of Deceased COVID-19 Patients.
To report the presence of viral ribonucleic acid (RNA) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in human retina in deceased patients with confirmed novel coronavirus disease 2019 (COVID-19). ⋯ Viral RNA of SARS-CoV-2 is detectable in the retina of COVID-19 patients.
-
Ocul. Immunol. Inflamm. · Jul 2020
EditorialEvolving Consensus Experience of the IUSG-IOIS-FOIS with Uveitis in the Time of COVID-19 Infection.
This document summarizes the experience of the International Uveitis Study Group (IUSG), the Intraocular Inflammation Society (IOIS), and the Foster Ocular Inflammation Society (FOIS) and can aid as a guide for the treatment of uveitis patients in the era of COVID-19 pandemic.
-
Ocul. Immunol. Inflamm. · Jul 2020
Ocular Manifestations of Hospitalized Patients with COVID-19 in Northeast of Iran.
To evaluate ocular findings in patients with Coronavirus Disease 2019 (COVID-19) in the Northeast of Iran. ⋯ Ocular manifestation was observed in more than half of our COVID-19 patients. Hence, it seems important to involve ophthalmologist in the diagnosis and management of these patients.
-
The spike proteins of SARS-CoV-2 interact with ACE2 or basigin/CD147 receptors, regulating human-to-human transmissions of COVID-19 together with serine protease TMPRSS2. The expression of these receptors on the ocular surface is unknown. ⋯ The ocular surface may represent an entry point for the SARS-CoV-2 in the human body. The conjunctiva and the cornea can adopt antiviral countermeasures which may explain the low prevalence of eye involvement.
-
Ocul. Immunol. Inflamm. · Jan 2018
Observational StudyEfficacy of Anti-TNF-α Therapy for the Treatment of Non-infectious Uveitis: A Retrospective Study of 21 Patients.
To assess the efficacy of anti-TNF alpha (TNF-α) therapy in patients with non-infectious uveitis. ⋯ Our study confirms the efficacy of anti-TNF for the control of short-term and long-term ocular inflammation, with high rates of complete clinical remission.